Advertisement

Proinflammatory and Antiinflammatory Mediators in Critical Illness

  • Daniel G. Remick
Chapter
  • 999 Downloads

Keywords

Soluble Receptor Status Asthmaticus Antiinflammatory Mediator Cytokine Inhibitor Pulmonary Sarcoidosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    LeMay LG, Vander AJ, Kluger MJ. Role of interleukin 6 in fever in rats. Am J Physiol 1990;258(3 Pt 2):R798–R80.3PubMedGoogle Scholar
  2. 2.
    Leon LR, White AA, Kluger MJ. Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am J Physiol 1998;275(1 Pt 2):R269–R277.PubMedGoogle Scholar
  3. 3.
    Long NC, Otterness I, Kunkel SL, Vander AJ, Kluger MJ. Roles of interleukin 1 beta and tumor necrosis factor in lipopolysaccharide fever in rats. Am J Physiol 1990;259:R724–R728.PubMedGoogle Scholar
  4. 4.
    Remick DG. Cytokine therapeutics for the treatment of sepsis: why has nothing worked? 2003;9(1):75–82.CrossRefGoogle Scholar
  5. 5.
    Thomson AW, Lotze MT, eds. The Cytokine Handbook: 4th edition. New York: Academic Press, 2003.Google Scholar
  6. 6.
    Remick DG, Kunkel RG, Larrick JW, Kunkel SL. Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest 1987;56: 583–590.PubMedGoogle Scholar
  7. 7.
    Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470–474.PubMedCrossRefGoogle Scholar
  8. 8.
    Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666–3670.PubMedCrossRefGoogle Scholar
  9. 9.
    Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1975;378(6552): 88–91.CrossRefGoogle Scholar
  10. 10.
    Kobayashi K, Kai M, Gidoh M, et al. The possible role of interleukin (IL)-12 and interferon-gamma-inducing factor/IL-18 in protection against experimental Mycobacterium leprae infection in mice. Clin Immunol Immunopathol 1998;88(3):226–231.PubMedCrossRefGoogle Scholar
  11. 11.
    Sivakumar PV, Foster DC, Clegg CH. Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumour responses. Immunology 2004;112(2):177–182.PubMedCrossRefGoogle Scholar
  12. 12.
    Waldmann T. The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases. Arthritis Res 2002;4(Suppl 3):S161–S167.PubMedCrossRefGoogle Scholar
  13. 13.
    Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA. Six at six: interleukin-6 measured 6h after the initiation of sepsis predicts mortality over 3 days. Shock 2002;17(6):463–467.PubMedCrossRefGoogle Scholar
  14. 14.
    Remick DG. Mediators of sepsis. In: Dietch EA, Vincent JL, Windsor A, eds. Sepsis and Multiple Organ Dysfunction. New York: WB Saunders; 2002:63–72.Google Scholar
  15. 15.
    Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004;25(2):75–84.PubMedCrossRefGoogle Scholar
  16. 16.
    IUIS/Who Subcommittee on Chemokine Nomenclature. Chemokine/chemokine receptor nomenclature. Cytokine 2003;21(1):48–49.CrossRefGoogle Scholar
  17. 17.
    Gately MK, Wilson DE, Wong HL. Synergy between recombinant interleukin 2 (rIL 2) and IL 2–depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro. J Immunol 1986;136(4):1274–1282.PubMedGoogle Scholar
  18. 18.
    Oppmann B, Lesley R, Blom B, et al. Kastelein. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13(5):715– 725.PubMedCrossRefGoogle Scholar
  19. 19.
    Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002;16(6):779–790.PubMedCrossRefGoogle Scholar
  20. 20.
    Gray PW, Goeddel DV. Structure of the human immune interferon gene. Nature 1982;298(5877):859–863.PubMedCrossRefGoogle Scholar
  21. 21.
    Schreiber RD, Pace JL, Russell SW, Altman A, Katz DH. Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon. J Immunol 1983; 131(2):826–832.PubMedGoogle Scholar
  22. 22.
    Kohno T, Brewer MT, Baker SL, Schwartz PE, et al. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci USA 1990;87: 8331–8335.PubMedCrossRefGoogle Scholar
  23. 23.
    Muller-Newen G, Kuster A, Hemmann U, Keul R, et al. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 1998;161(11):6347–6355.PubMedGoogle Scholar
  24. 24.
    Sims JE, Giri JG, Dower SK. The two interleukin-1 receptors play different roles in IL-1 actions. Clin Immunol Immunopathol 1994;72: 9–14.PubMedCrossRefGoogle Scholar
  25. 25.
    Dinarello CA. Novel targets for interleukin 18 binding protein. Ann Rheum Dis 2001;60 Suppl 3:iii18–iii24.PubMedGoogle Scholar
  26. 26.
    Carter DB, Deibel MR Jr, Dunn CJ, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein [see comments]. Nature 1990;344:633–638.PubMedCrossRefGoogle Scholar
  27. 27.
    Yokota T, Otsuka T, Mosmann T, et al. Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell– and T-cell–stimulating activities. Proc Natl Acad Sci USA 1986;83(16):5894–5898.PubMedCrossRefGoogle Scholar
  28. 28.
    Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli DS, Hamilton JA. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci USA 1989;86(10):3803–3807.PubMedCrossRefGoogle Scholar
  29. 29.
    Standiford TJ, Strieter RM, Chensue SW, et al. IL-4 inhibits the expression of IL-8 from stimulated human monocytes. J Immunol 1990; 145(5):1435–1439.PubMedGoogle Scholar
  30. 30.
    Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170(6):2081–2095.PubMedCrossRefGoogle Scholar
  31. 31.
    de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174;1209–1220.PubMedCrossRefGoogle Scholar
  32. 32.
    de Waal Malefyt R, Figdor CG, Huijbens R, et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 1993;151(11):6370–6381.PubMedGoogle Scholar
  33. 33.
    McFadden G, Graham K, Ellison K, et al. Interruption of cytokine networks by poxviruses: lessons from myxoma virus. J Leukocyte Biol 1995;57(5):731–738.PubMedGoogle Scholar
  34. 34.
    Barner M, Mohrs M, Brombacher F, Kopf M. Differences between IL-4R alpha-deficient and IL-4–deficient mice reveal a role for IL-13 in the regulation of Th2 responses. Curr Biol 1998;8(11):669–672.PubMedCrossRefGoogle Scholar
  35. 35.
    Moses HL, Branum EL, Proper JA, Robinson RA. Transforming growth factor production by chemically transformed cells. Cancer Res 1981; 41(7):2842–2848.PubMedGoogle Scholar
  36. 36.
    Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D. Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol 2005;12(1):60–67.PubMedGoogle Scholar
  37. 37.
    Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, Dayer JM. Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology 1992;76(1):20–23.Google Scholar
  38. 38.
    Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002;13(4–5):323–340.PubMedCrossRefGoogle Scholar
  39. 39.
    Arend WP, Gabay C. Cytokines in the rheumatic diseases. Rheum Dis Clin North Am 2004;30(1):41–67, v–vi.PubMedCrossRefGoogle Scholar
  40. 40.
    Ludwiczek O, Vannier E, Borggraefe I, et al. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol 2004;138(2):323–329.PubMedCrossRefGoogle Scholar
  41. 41.
    Cohen SB. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 2004;30(2):365–380, vii.PubMedCrossRefGoogle Scholar
  42. 42.
    Piguet PF, Vesin C, Grau GE, Thompson RC. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 1993;5(1):57–61.PubMedCrossRefGoogle Scholar
  43. 43.
    Seekamp A, Warren JS, Remick DG, Till GO, Ward PA. Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury. Am J Pathol 1993;143: 453–463.PubMedGoogle Scholar
  44. 44.
    Selig W, Tocker J. Effect of interleukin-1 receptor antagonist on antigen-induced pulmonary responses in guinea pigs. Eur J Pharmacol 1992;213(3):331–336.PubMedCrossRefGoogle Scholar
  45. 45.
    Tillie-Leblond I, Pugin J, Marquette CH, et al. Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus. Am J Respir Crit Care Med 1999; 159(2):487–494.PubMedGoogle Scholar
  46. 46.
    Mikuniya T, Nagai S, Takeuchi M, et al. Significance of the interleukin-1 receptor antagonist/interleukin-1 beta ratio as a prognostic factor in patients with pulmonary sarcoidosis. Respiration 2000;67(4):389–396.PubMedCrossRefGoogle Scholar
  47. 47.
    Akalin H, Akdis AC, Mistik R, Helvaci S, Kilicturgay K. Cerebrospinal fluid interleukin-1 beta/interleukin-1 receptor antagonist balance and tumor necrosis factor-alpha concentrations in tuberculous, viral and acute bacterial meningitis. Scand J Infect Dis 1994;26(6):667–674.PubMedCrossRefGoogle Scholar
  48. 48.
    Smith D R, Kunkel SL, Standiford TJ, et al. Increased interleukin-1 receptor antagonist in idiopathic pulmonary fibrosis. A compartmental analysis. Am J Respir Crit Care Med 1995;151(6):1965–1973.PubMedGoogle Scholar
  49. 49.
    Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990;348(6301):550–552.PubMedCrossRefGoogle Scholar
  50. 50.
    Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin 1 prevents Escherichia coli–induced shock in rabbits. FASEB J 1991;5:338–343.PubMedGoogle Scholar
  51. 51.
    Fisher CJ Jr, Dhainaut JF, Opal SM, Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group [see comments]. JAMA 1994;271:1836–1843.CrossRefGoogle Scholar
  52. 52.
    Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005;115(1):1–20.PubMedCrossRefGoogle Scholar
  53. 53.
    Kaneyama K, Segami N, Sun W, Sato J, Fujimura K. Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005:99(3);276–284.PubMedCrossRefGoogle Scholar
  54. 54.
    Taylor PC. Anti-TNFalpha therapy for rheumatoid arthritis: an update. Internal Medicine. 2003;42(1):15–20.PubMedCrossRefGoogle Scholar
  55. 55.
    Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn’s disease, sepsis, and myelodysplastic syndromes. Microscopy Res Technique 2000;50(3):229–235.CrossRefGoogle Scholar
  56. 56.
    Lekander M, Elofsson S, Neve IM, Hansson LO, Unden AL. Self-rated health is related to levels of circulating cytokines. Psychosom Med 2004;66(4):559–563.PubMedCrossRefGoogle Scholar
  57. 57.
    Barash J, Dushnitzki D, Barak Y, Miron S, Hahn T. Tumor necrosis factor (TNF)alpha and its soluble receptor (sTNFR) p75 during acute human parvovirus B19 infection in children. Immunol Lett 2003;88(2):109–112.PubMedCrossRefGoogle Scholar
  58. 58.
    Radhakrishnan VV, Sumi MG, Reuben S, Mathai A, Nair MD. Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome. Acta Neurol Scand 2004;109(1):71–74.PubMedCrossRefGoogle Scholar
  59. 59.
    Park WY, Goodman RB, Steinberg KP, et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;164(10 Pt 1):1896–1903.PubMedGoogle Scholar
  60. 60.
    Millo JL, Schultz MJ, Williams C, et al. Compartmentalisation of cytokines and cytokine inhibitors in ventilator-associated pneumonia. Intensive Care Med 2004;30(1):68–74.PubMedCrossRefGoogle Scholar
  61. 61.
    Ashare A, Powers LS, Butler NS, Doerschug KC, Monick MM, Hunninghake GW. Anti-inflammatory response is associated with mortality and severity of infection in sepsis. Am J Physiol Lung Cell Mol Physiol 2005;288(4):L633–L640.PubMedCrossRefGoogle Scholar
  62. 62.
    Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock—a review of laboratory models and a proposal. J Surg Res 1980;29: 189–201.PubMedCrossRefGoogle Scholar
  63. 63.
    Ebong SJ, Call DR, Bolgos G, et al. Immunopathologic responses to non-lethal sepsis. Shock 1999;12(2):118–126.PubMedCrossRefGoogle Scholar
  64. 64.
    Ebong S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun 1999;67(12):6603–6610.PubMedGoogle Scholar
  65. 65.
    Xanthoulea S, Pasparakis M, Kousteni S, et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 2004;200(3):367–376.PubMedCrossRefGoogle Scholar
  66. 66.
    Rothe J, Lesslauer W, Lotscher H, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993; 364(6440):798–802.PubMedCrossRefGoogle Scholar
  67. 67.
    Butty VL, Roux-Lombard P, Garbino J, Dayer JM, Ricou B. Anti- inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis. Eur Cytokine Netw 2003;14(1):15–19.PubMedGoogle Scholar
  68. 68.
    Bone RC, Balk RA, Cerra FB, Dellinger RP, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine [see comments]. Chest 1992;101:1644–1655.PubMedCrossRefGoogle Scholar
  69. 69.
    Hotchkiss RS, Karl IE. Medical progress: the pathophysiology and treatment of sepsis. N Engl J Med 2003;348(2):138–150.PubMedCrossRefGoogle Scholar
  70. 70.
    Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 2001;16(2): 83–96.PubMedCrossRefGoogle Scholar
  71. 71.
    Call DR, Nemzek JA, Ebong SJ, Bolgos GL, Newcomb DE, Remick DG. Ratio of local to systemic chemokine concentrations regulates neutrophil recruitment. American Journal of Pathology 2001;158(2):715–721.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2009

Authors and Affiliations

  • Daniel G. Remick
    • 1
  1. 1.Professor of Pathology, Assistant Dean of AdmissionsUniversity of Michigan Medical SchoolAnn ArborUSA

Personalised recommendations